Genome Editing

Selected news for the healthcare topic - Genome Editing, collected since 10/2017. Recent stories appear in zolmax.com and Mayfield Recorder. This healthcare topic shares news with CRISPR, Precision BioSciences, Intellia Therapeutics, Gene Therapy, Rare Diseases and over a hundred others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
5/7/2021 Editas Medicine (NASDAQ:EDIT) versus Precision BioSciences (NASDAQ:DTIL) Critical Analysis zolmax.com ... currently the more affordable of the two stocks.SummaryPrecision BioSciences beats Editas Medicine on 7 of the 13 factors compared between the two stocks.About Editas MedicineEditas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The ...
5/7/2021 Editas Medicine (NASDAQ:EDIT) and Precision BioSciences (NASDAQ:DTIL) Head-To-Head Review Mayfield Recorder ... believe Precision BioSciences is more favorable than Editas Medicine.SummaryPrecision BioSciences beats Editas Medicine on 7 of the 13 factors compared between the two stocks.Precision BioSciences Company ProfilePrecision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The Therapeutic segment develops allogeneic CAR ...
5/4/2021 Small-Molecule Cocktail To Improve Stem Cell Use pioneeringminds.com ... The researchers suggest that the cocktail could enhance the potential therapeutic uses of stem cells, ranging from treating diseases and conditions — such as diabetes, Parkinson’s disease, and spinal cord injury — to genome editing . Human pluripotent stem cells are cells that, in theory, can grow forever and serve as an inexhaustible source for specialized cells, such as brain, kidney, and heart cells. But stem cells are sensitive, and ...
5/3/2021 Scientists identify small-molecule cocktail to improve stem cell use in research and disease treatments National Institutes of Health ... The researchers suggest that the cocktail could enhance the potential therapeutic uses of stem cells, ranging from treating diseases and conditions — such as diabetes, Parkinson’s disease and spinal cord injury — to genome editing .Human pluripotent stem cells are cells that, in theory, can grow forever and serve as an inexhaustible source for specialized cells, such as brain, kidney and heart cells. But stem cells are sensitive, and ...
4/29/2021 CRISPR prime editing with ribonucleoprotein complexes in zebrafish and primary human cells | Nature Biotechnology Nature ... Y. & Medova, M. A comparative analysis of individual RAS mutations in cancer biology. Front. Oncol. 9 , 1088 (2019). Article Google Scholar 13. Jao, L. E., Wente, S. R. & Chen, W. Efficient multiplex biallelic zebrafish genome editing using a CRISPR nuclease system. Proc. Natl Acad. Sci. USA 110 , 13904–13909 (2013). CAS Article Google Scholar 14. Levy, J. M. et al. Cytosine and adenine base editing of the brain, liver, retina ...
4/28/2021 Synthetic Biology Market worth USD 19.8 billion : increasing investments in the Bioinformatics Technology express-press-release.net ... of the segment can be attributed to the rising demand for synthetic DNA, synthetic RNA, and oligonucleotides across various application industries and its increasing use with genome engineering for the ease and efficiency in genome editing and genome targeting.The APAC market is expected to grow at the highest CAGR during the forecast periodThe market in the Asia Pacific is expected to grow at the highest CAGR during the ...
4/27/2021 Edigene secures $62M in series B+ to advance hematopoietic stem cell therapy 04-27 BioWorld Genome editing startup Edigene Inc. closed a ¥400 million (US$62 million) series B+ round to expand its operation to more cities and advance its lead product ET-01 into clinical trials. The financing follows the $67 million series B that closed in October 2020 ...
4/26/2021 Genome Editing Market Complete survey 2019-2026 Insights, Demand, Analysis, Manufacturers, Type and Application | Market Expertz Wordpress.com The Genome Editing market report focuses on the economic developments and consumer spending trends across different countries for the forecast period 2019 to 2026. The research further reveals which countries and regions will have a better standing in the years to come. Apart from this, the study talks about the growth rate, market share as well as the recent developments in the Genome Editing industry worldwide. Besides, the special mention ...
4/26/2021 Human genome editing requires difficult conversations between science and society wisc.edu Human genome editing requires difficult conversations between science and society April 26, 2021 By For news media More informationIn October of 2020, Jennifer Doudna and Emmanuelle Charpentier were awarded the Nobel Prize in chemistry for their discovery of an adaptable, easy way to edit genomes, known as CRISPR, which has transformed the world of genetic engineering.CRISPR has been used to fight lung cancer and correct the mutation responsible ...
4/26/2021 Human genome editing requires difficult conversations between science and society Phys Org ... Dietram A. Scheufele el al., "What we know about effective public engagement on CRISPR and beyond," PNAS (2021). www.pnas.org/cgi/doi/10.1073/pnas.2004835117 Journal information: Provided by University of Wisconsin-Madison Citation : Human genome editing requires difficult conversations between science and society (2021, April 26) human-genome-requires-difficult-conversations.html ...
4/24/2021 507PFT, Associate Scientist / Senior Research Associate, Molecular Engineering (Genome Editing and Next Generation Sequencing) fatetherapeutics.com 507PFT, Associate Scientist / Senior Research Associate, Molecular Engineering (Genome Editing and Next Generation Sequencing) Job Code 507PFT currently seeking a talented and motivated individual with expertise in cell and molecular biology to join a multidisciplinary team dedicated to discovery and productization of novel off-the-shelf cell-based immunotherapies. This position will perform cell culture of induced pluripotent stem cells (iPSCs) to support Fate’s gene editing platform and preclinical ...
4/24/2021 CRISPR and CRISPR-Associated (Cas) Genes Market 2020 Overview Along with Merck KGaA,Addgene,CRISPR THERAPEUTICS,Thermo Fisher Scientific, Inc.,Mirus Bio LLC. vitalnews24.com ... Market aims at developing a better understanding of the CRISPR and CRISPR-Associated (Cas) Genes Industry through qualitative and quantitative analysis of the key market parameters.CRISPR and CRISPR-Associated (Cas) Genes is a genome editing tool that enables the researchers to make changes in the DNA. CRISPR-Cas9 stands for clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9. In recent years the CRISPR and CRISPR-Associated ...
4/23/2021 Shining a light on innovation in the amenity sector landscapeandamenity.com ... Royal Holloway, University of London, on biological control, from Dr Ruth Mann from STRI on innovations in sports, lawn and urban green spaces and from Dr Penny Hundleby from the John Innes Institute on genome editing and what it can offer.Ian Graham, from Complete Weed Control, also considers what innovation can offer in his area of work.The publication can be accessed here: https://amenityforum.co.uk/wp-content/uploads/2021/04 ...
4/23/2021 Genome Editing In Farm Animals pioneeringminds.com Frontiers DNA Editing Technology Hope 2 views Genome Editing In Farm Animals Researchers at the TUM have demonstrated a way to efficiently study molecular mechanisms of disease resistance or biomedical issues in farm animals. Researchers are now able to introduce specific gene mutations into the desired organ or even correct existing genes without creating new animal models for each target gene. This reduces the number of animals required for research ...
4/23/2021 Farming for net zero with Cereals 2021 blogspot.com ... emerging scientific developments to help farmers adapt to and mitigate climate change, explains event director, Alli McEntyre. 'We have top researchers and farmer speakers covering topics from carbon credit schemes to the possibilities of genome editing , looking at both the challenges and opportunities ahead.' An essential part of CHAP's mission is to provide the solutions, networks and expertise needed to support this journey, and further enhance sustainable farming practices, says ...
4/22/2021 A high-tech expansion salemnews.com Close 1 of 2JAIME CAMPOS/Staff photoBrett Robb, the scientific director for RNA and genome editing for New England Biolabs, said 40 to 45 people, mostly research scientists, will move from New England Biolabs in Ipswich to the new 33,000-square-foot Beverly location. Jaime CamposJAIME CAMPOS/Staff photoBrett Robb, the scientific director for RNA and genome editing for New England Biolabs, stands in a space that will ...
4/22/2021 CRISPR bakin’: Intellia on sizzle as Wall Street crunches available data | 2021-04-22 | BioWorld BioWorld ... news due in the near-term future from the sector will spill from Intellia Therapeutics Inc., of Cambridge, Mass., which is due to roll out first-in-human data with a systemic CRISPR-based genome editing therapy, NTLA-2001, in hereditary transthyretin amyloidosis ...
4/22/2021 Genome Editing Company EdiGene Raises RMB 400M in Series B Plus Financing Round genomeweb.com Apr 22, 2021 staff reporter Save for laterNEW YORK – Genome editing company EdiGene said on Wednesday that it has raised RMB 400 million ($62 million) in a Series B Plus financing round.Loyal Valley Capital led the round, which also included new investors BioTrack Capital and Sherpa Healthcare Partners and existing investors IDG Capital, Lilly Asia Venture, 3H Health Investment, Huagai Capital, Sequoia Capital China, Alwin Capital, and ...
4/21/2021 Stanford's Hank Greely on CRISPR People and Designer Babies - Legal Aggregate - Stanford Law School Stanford ... along their traits to future generations, has entertained sci-fi fans for decades. But in the real world, it has remained taboo, and for good reason: assuming it could even be accomplished, “human germline genome editing ,” as it is called, poses daunting ethical and safety issues that have caused scientists to eschew it.That changed in 2018 when a Chinese scientist, Dr. He Jiankui (known as JK), announced the ...
4/21/2021 Edigene secures $62M in series B+ to advance hematopoietic stem cell therapy 04-21 BioWorld Genome editing startup Edigene Inc. closed a ¥400 million (US$62 million) series B+ round to expand its operation to more cities and advance its lead product ET-01 into clinical trials. The financing follows the $67 million series B that closed in October 2020 ...